Your browser doesn't support javascript.
loading
Tissue-Specific Oncogenic Activity of KRASA146T.
Poulin, Emily J; Bera, Asim K; Lu, Jia; Lin, Yi-Jang; Strasser, Samantha Dale; Paulo, Joao A; Huang, Tannie Q; Morales, Carolina; Yan, Wei; Cook, Joshua; Nowak, Jonathan A; Brubaker, Douglas K; Joughin, Brian A; Johnson, Christian W; DeStefanis, Rebecca A; Ghazi, Phaedra C; Gondi, Sudershan; Wales, Thomas E; Iacob, Roxana E; Bogdanova, Lana; Gierut, Jessica J; Li, Yina; Engen, John R; Perez-Mancera, Pedro A; Braun, Benjamin S; Gygi, Steven P; Lauffenburger, Douglas A; Westover, Kenneth D; Haigis, Kevin M.
Afiliação
  • Poulin EJ; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Bera AK; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Lu J; Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
  • Lin YJ; Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
  • Strasser SD; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Paulo JA; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Huang TQ; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Morales C; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Yan W; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Cook J; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts.
  • Nowak JA; Department of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
  • Brubaker DK; Department of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
  • Joughin BA; Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
  • Johnson CW; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • DeStefanis RA; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Ghazi PC; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Gondi S; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Wales TE; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Iacob RE; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Bogdanova L; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Gierut JJ; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Li Y; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Engen JR; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Perez-Mancera PA; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Braun BS; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Gygi SP; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Lauffenburger DA; Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
  • Westover KD; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts.
  • Haigis KM; Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts.
Cancer Discov ; 9(6): 738-755, 2019 06.
Article em En | MEDLINE | ID: mdl-30952657
ABSTRACT
KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRASG12D, a common mutant form, and KRASA146T, a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRASA146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor-induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRASG12D and KRASA146T exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer.

SIGNIFICANCE:

Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.See related commentary by Hobbs and Der, p. 696.This article is highlighted in the In This Issue feature, p. 681.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncogenes / Proteínas Proto-Oncogênicas p21(ras) / Alelos / Mutação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncogenes / Proteínas Proto-Oncogênicas p21(ras) / Alelos / Mutação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2019 Tipo de documento: Article